Local
AEON Biopharma Advances Botox Biosimilar Candidate
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Orange County Business Journal

Aliso Viejo-based AEON Biopharma Inc. reported third-quarter net income of $2.5 million, compared with a $4.5 million loss a year ago. The company, which is developing a biosimilar candidate to Botox for therapeutic uses, received additional feedback from the FDA on its development strategy. AEON submitted an investigational new drug application for a comparative study, which it expects to begin in the first quarter of 2027. The company also received approximately $6.2 million from warrant exercises, extending its cash reserves into the second quarter of 2027.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Orange County Business Journal



